Prevention & Treatment
Currently, there is no adenovirus vaccine available for the general public.
A vaccine against adenovirus types 4 and 7 was given to U.S. military recruits from 1971 to 1999. The manufacturer stopped producing the vaccine in 1999. A new live, oral vaccine against adenovirus types 4 and 7 was approved by the U.S. Food and Drug Administration in March 2011 for U.S. military personnel 17 through 50 years old. The vaccine is recommended by the U.S. Department of Defense for military recruits entering basic training in order to prevent acute respiratory disease. For more information about the vaccine, see Adenovirus Vaccine Information Statement (VIS).
To prevent nosocomial outbreaks of adenovirus infections, health care providers should strictly follow infection control practices, including contact and droplet precautions.
Health care providers should follow the guidelines for preventing health care associated pneumonia for suspected cases of adenoviral pneumonia.
Strict attention to infection control practices, including contact and droplet precautions, is effective for stopping health care associated outbreaks of adenovirus infections, such as epidemic keratoconjunctivitis. Guidelines for care of patients with pneumonia should be followed in cases of suspected adenoviral pneumonia.
Most adenovirus infections are mild and typically require only treatment of symptoms.
There is no specific therapy for adenoviruses. However, cidofovir has been used to treat severe adenovirus infections in people with immunocompromised systems.
Serious adenovirus infections can only be managed by treating symptoms and complications of the infection.
For more information, see
- Page last reviewed: December 27, 2011
- Page last updated: December 27, 2011
- Content source: